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Mutations in the ﬁbrillin-1 (FBN1) gene cause Marfan syndrome (MFS) and have been associated with a wide range of
overlapping phenotypes. Clinical care is complicated by variable age at onset and the wide range of severity of aortic
features. The factors that modulate phenotypical severity, both among and within families, remain to be determined.
The availability of international FBN1 mutation Universal Mutation Database (UMD-FBN1) has allowed us to perform
the largest collaborative study ever reported, to investigate the correlation between the FBN1 genotype and the nature
and severity of the clinical phenotype. A range of qualitative and quantitative clinical parameters (skeletal, cardiovascular,
ophthalmologic, skin, pulmonary, and dural) was compared for different classes of mutation (types and locations) in
1,013 probands with a pathogenic FBN1 mutation. A higher probability of ectopia lentis was found for patients with a
missense mutation substituting or producing a cysteine, when compared with other missense mutations. Patients with
an FBN1 premature termination codon had a more severe skeletal and skin phenotype than did patients with an inframe
mutation. Mutations in exons 24–32 were associated with a more severe and complete phenotype, including younger
age at diagnosis of type I ﬁbrillinopathy and higher probability of developing ectopia lentis, ascending aortic dilatation,
aortic surgery, mitral valve abnormalities, scoliosis, and shorter survival; the majority of these results were replicated
even when cases of neonatal MFS were excluded. These correlations, found between different mutation types and clinical
manifestations, might be explained by different underlying genetic mechanisms (dominant negative versus haploinsuf-
ﬁciency) and by consideration of the two main physiological functions of ﬁbrillin-1 (structural versus mediator of TGFb
signalling). Exon 24–32 mutations deﬁne a high-risk group for cardiac manifestations associated with severe prognosis
at all ages.
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Marfan syndrome (MFS [MIM 154700]) is a connective-
tissue disorder, with autosomal dominant inheritance and
a prevalence of 1 in 5,000–10,000 individuals.1 The car-
dinal features of MFS involve the ocular, cardiovascular,
and skeletal systems.2 The skin, lung, and dura may also
be involved. MFS is notable for its variability in age at
onset, tissue distribution, and severity of clinical mani-
festations, both among and within affected families. Be-
cause of the high population frequency and the nonspe-
ciﬁc nature of many of the clinical ﬁndings for MFS,
clinical diagnostic criteria for this disorder have been es-
tablished,3–4 the latest being the Ghent criteria, which su-
perseded the previous so-called Berlin criteria.
Study of the molecular determinants of phenotypical
variations in MFS has been possible only since the iden-
tiﬁcation of the causative ﬁbrillin-1 (FBN1) gene5 (MIM
134797). Fibrillin-1 has a modular structure, with 47 re-
peats of six-cysteine epidermal-growth-factor (EGF)–like
motifs, 43 of which are of the calcium-binding (cb) type
(cb-EGF).6 Fibrillin-1 monomers associate to form com-
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Table 1. Number of Patients Recruited to the Study and
Their Laboratory of Origin
Origin
No. of Patients
(Laboratories)
Belgium 167 (1)
United Kingdom 166 (7)
Germany 156 (4)
France 154 (3)
United States 146 (8)
Italy 89 (2)
Australia 80 (1)
Asia 22 (6)
Other European countries 22 (3)
Other North and South American countries 11 (2)
Total 1,013 (37)
plex extracellular macroaggregates, termed “microﬁbrils,”
which are important for the integrity and homeostasis of
both elastic and nonelastic tissues.7–8 The protein also con-
tains seven eight-cysteine motifs, which bear homology
to motifs found in the latent transforming-growth-factor
beta–binding proteins (TGFb-BPs), and a proline-rich re-
gion. The relationship between FBN1 and TGFb signaling
has been underscored by the identiﬁcation of mutations
in TGFBR2 (MIM 190182) in patients with MFS and Mar-
fan-like conditions9 and in pathological studies in knockin
and knockout mice.10 Indeed, ﬁbrillins and TGFb-BPs con-
stitute a family of structurally related and interacting pro-
teins. In MFS mouse models, deﬁciency of ﬁbrillin-1 alters
matrix sequestration of the large latent complex of TGFb,
rendering the cytokine more prone for activation.10 Re-
cently, a speciﬁc ﬁbrillin-1 sequence encoded by exons 44–
49 has been shown to regulate the bioavailability of en-
dogenous TGFb1.11
Two major mutation categories—premature termina-
tion codons (PTCs) and inframe mutations—have been
reported in the FBN1 gene.12 A total of 559 pathogenic
mutations were reported in the last update of the Uni-
versal Marfan Database (UMD)–FBN1,12 and most of
these are unique to individual families. Two-thirds aremis-
sense mutations, the majority of which are cysteine
substitutions.
Besides classic MFS, mutations in FBN1 have been as-
sociated with a broad spectrum of phenotypes, including
neonatal MFS,13 isolated ectopia lentis14 (MIM 129600),
isolated ascending aortic aneurysm and dissection,15 iso-
lated skeletal features,16,17 and Weill-Marchesani syn-
drome18 (MIM 608328). So far, genotype-phenotype cor-
relations in FBN1 have been weak except for the cluster
of mutations in exons 24–32 reported in neonatal
MFS.13,19–22
Indeed, previous reported studies investigating geno-
type-phenotype correlations were performed with a max-
imum of 101 patients.23–27 Those authors compared pa-
tients with mutations leading to a PTC versus patients
with missense mutations, as well as subjects withmissense
mutations involving a cysteine versus individuals with
other missense mutations. Moreover, they focused onma-
jor cardiac, ocular, and skeletal involvement. Differences
between the groups, with regard to patients’ age at follow-
up, were not taken into account.
Large sets of both clinical andmolecular data are needed
to study (1) the association between FBN1 mutation type
and severity of the disease and (2) the speciﬁcity of organ
involvement in relation to a mutation type. The inter-
national UMD-FBN1, set up in 1995, provides these data
for 1,013 probands with known FBN1mutationswhowere
recruited from specialized MFS clinics all over the world.
We report the results of the statistical analysis of these
data. These results provide possible clues into pathophys-
iological processes.
Patients, Material, and Methods
Patients
A total of 1,191 probands who had received a diagnosis of MFS
or another type I ﬁbrillinopathy were identiﬁed between 1995
and 2005 via the framework of the UMD-FBN112 andparticipating
centers. The inclusion criteria in our study were (1) the presence
of a heterozygous pathogenic FBN1 gene mutation and (2) the
availability of clinical information.
Overall, 178 patients (15%) had to be excluded from the study
(no clinical data available for 129; insufﬁcient data about cardiac,
ocular, or skeletal involvement for 44; two different mutations
on the same allele for 4; and compound heterozygosity for FBN1
mutations for 1). The 1,013 patients included in our study orig-
inated from 38 countries on ﬁve continents. The majority (72%)
were white Europeans or were of European ancestry, 14% were
from North and South America, 8% were from Oceania, 4% were
from Asia, and 2% were from Africa. Table 1 summarizes the
participation of the different laboratories in the study. Patient age
at inclusion ranged from birth to 72 years. The clinical data
were collected mainly from standardized questionnaires sent to
the referring physician, and a minority were from previous
publications that reported sufﬁcient clinical data. The clinical
information included a range of qualitative and quantitative clin-
ical parameters, including age at diagnosis of MFS or another type
I ﬁbrillinopathy and the presence or absence of clinical features
including cardiac, ophthalmologic, skeletal, dermal, pulmonary,
and dural manifestations. The age at diagnosis and at surgery for
aortic dilatation, ectopia lentis, and scoliosis was also noted. All
questionnaires were collected by one individual (L.F.) to rule out
duplication of patients in the study. To avoid bias as a result of
familial clustering, affected family members of a proband were
not included in the analysis.
The pathogenic nature of a putative mutation was assessed us-
ing recognized criteria. In brief, all nonsense mutations, all de-
letions or insertions (in or out of frame) were considered path-
ogenic; for all splice mutations, the wild-type and mutant
strength values of the splice sites were compared using genetic
algorithms,28–30 and only mutations displaying signiﬁcant devi-
ation from the norm were included. Missense mutations were
considered pathogenic when at least one of the following features
was found: (1) de novo missensemutation, (2)missensemutation
substituting or creating a cysteine, (3) missense mutation in-
volving a consensus cb residue,21 (4) substitution of glycines im-
plicated in correct domain-domain packing,31 and (5) intrafam-
ilial segregation of a missense mutation involving a conserved
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Table 2. Frequency of Clinical Features in the Different Systems Involved in MFS
and Type I Fibrillinopathies ( )Np 1,013
System and Clinical Feature(s)
No. of
Events
No. of
Available Data Percentage
Skeletal:
Arachnodactyly 751 969a 78
Dolichostenomelia 522 947a 55
Joint laxity 600 956a 63
Scoliosis 508 965a 53
Pectus deformityb 570 962a 59
Limited elbow extension 153 974a 16
Protrusio acetabulae 69 298a 23
Facial dysmorphism 443 913a 49
High-arched palate 639 932a 69
Dental malocclusion 372 843a 44
Pes planus 402 864a 47
Orthopedic surgery 113 983a 12
Major skeletal involvement 327 1,013 32
Minor skeletal involvement 564 1,013 56
Ocular:
Ectopia lentis 542 1,013 54
Myopia 453 865 52
Cataract 39 983 4
Retinal detachment 65 980 7
Glaucoma 19 905 2
Surgery for ectopia lentis 122 910 13
Other eye surgeries 43 905 5
Major eye involvement 542 1,013 54
Cardiac:
Dilatation of the ascending aorta 775 1,013 77
Dissection of the ascending aorta 145 1,013 14
Dilatation or dissection of the descending or
abdominal aorta before age 50 years 66 1,013 7
Mitral valve prolapse 533 983 54
Mitral regurgitation 313 959 33
Aortic insufﬁciency 205 975 21
Aortic surgery 282 1011 28
Isolated valvular surgery 45 1004 4
Major cardiac involvement 776 1,013 77
Minor cardiac involvement 108 1,013 11
Skin:
Striae 444 945 47
Herniae 96 988 10
Minor skin involvement 480 1,013 47
Lung:
Pneumothorax 73 1,002 7
Minor lung involvement 73 1,013 7
CNS:
Dural ectasia 154 292 53
Major CNS involvement 154 1,013 15
a Nineteen patients were classiﬁed as having minor, major, or neither minor nor major skeletal
features, but details about their skeletal manifestations were not available.
b Includes pectus excavatum, 246 (26%) of 962; pectus carinatum, 288 (30%) of 962; and undeﬁned
pectus malformation.
amino acid. For 38 mutations not displaying one of the above
features, additional data provided by SIFT,32,33 BLOSUM-62,34 and
biochemical values (Kristine Yu’s Web site) were gathered and
analyzed using a new UMD tool (M. Fre´de´ric, C. Boileau, D. Ham-
roun, M. Lalande, M. Claustres, C. Be´roud, G. Collod-Be´roud,
unpublished data).
Involvement of Different Organ Systems
The proportion of each speciﬁc clinical feature or system involved
was compared in the different groups of mutation types or lo-
cations. The following were each considered as a system: the skel-
eton, the eye, the heart, the skin, and the dura. The clinical fea-
tures of each system are listed in table 2. No attempts were made
to incorporate dilatation of the pulmonary artery, calciﬁcation of
the mitral valve annulus, apical blebs, ﬂat cornea and iris, or
ciliary muscle hypoplasia in the analyses, since those phenotypes
were rarely evaluated. Similarly, the axial globe length had rarely
been measured, and the deﬁnition of myopia varied widely from
center to center. For this reason, myopia of any degree was in-
cluded. In consequence, the presence or absence of minor oph-
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thalmological involvement could not be assessed. The ages at
diagnosis and at surgerywere collected for scoliosis, ectopia lentis,
and aortic dilatation or dissection. The probability of surgery for
ectopia lentis was studied only in the group of patients with
ectopia lentis. Similarly, the probability of aortic dissection and
surgery for aortic dilatation or dissection was studied only in the
group of patients with aortic dilatation. The number of systems
involved was also assessed according to the Ghent nosology.4
Patients were classiﬁed as having MFS if the diagnostic Ghent
nosology criteria were met, including the presence of an FBN1
mutation as a major feature and, in a second step, excluding the
presence of an FBN1 mutation as a major feature. All other pa-
tients were considered as displaying a type I ﬁbrillinopathy. For
the purpose of this study and in the absence of consensus di-
agnostic features, patients were classiﬁed as having neonatal MFS
when severe features of MFS, including severe valvular insufﬁ-
ciencies, were present before age 4 wk.
Mutation Screening
Mutation screening, with the consent of the patient or a guardian,
was performed in the 38 different laboratories by use of SSCP
analysis, denaturing high-performance liquid chromatography,
heteroduplex analysis, long-range RT-PCR, or direct sequencing
of RNA extracted from cell lines or of genomic DNA from pe-
ripheral-blood samples. PTC mutations were classiﬁed as those
that would be likely to produce no or a truncated FBN1 protein
(frameshifts, stop codons, and out-of-frame splice mutations),
whereas inframe mutations were classiﬁed as missense muta-
tions, inframe deletions/duplications, or inframe splice muta-
tions. Twenty-nine splice mutations could not be classiﬁed and
were therefore excluded from the analyses that compared types
of mutations.
Statistical Analysis
The frequency of many features of MFS increases with age. Since
the patients had different lengths of follow-up, x2 tests are not
appropriate for comparing clinical features between groups. Thus,
we used a time-to-event analysis technique to estimate a reliable
cumulative probability of observing the different manifestations
of MFS. This technique could be applied for the following events:
diagnosis of type I ﬁbrillinopathy and diagnosis of scoliosis, ec-
topia lentis, and/or aortic dilatation or dissection, as well as sur-
gery for these different manifestations, for which the ages at
diagnosis were systematically collected. In all time-to-event anal-
yses, the baseline date (time zero) was the date of birth. The time-
to-event diagnosis was deﬁned as the interval between the base-
line date and the date of ﬁrst observation of the event. Subjects
who did not manifest the studied event during the follow-up
course were censored at their last follow-up. Subjects for whom
the age at diagnosis of a speciﬁc manifestation was not available
were excluded from these analyses (a maximum of 4% of pa-
tients). The number of observations for each clinical feature is
indicated in table 2. The Kaplan-Meier method35 was used to es-
timate the cumulative probabilities of clinical manifestations of
the disease at ages 10, 25, and 40 years, to describe the diagnosis
of clinical features over time. Clinical differences among the dif-
ferent mutation groups (different locations or types of mutation)
were tested using the nonparametric log-rank test. Overall sur-
vival was also described and compared, using the same method,
according to the type/location of the mutation. To underline the
importance of taking into account the time to diagnosis of clinical
features, we compared the results obtained for aortic dilatation
using a x2 test and the time-to-event technique.
For the other features (skeletal features other than scoliosis,
skin, lung, and dural involvement) for which the age at diagnosis
was not collected, age at last follow-up was the only information
available about the time of observation of clinical features. To
indirectly take into account the patient’s length of follow-upeven
in this situation, we adjusted all comparisons of MFS manifes-
tation proportions for the age at last follow-up, categorized into
10-year age groups. These adjusted comparisons were performed
using the Mantel-Haenszel (MH) test.36 Since this test is appro-
priate only if the relationship between the mutation type and
the clinical manifestation is similar in the different strata of age
at last follow-up, we checked the homogeneity between strata
using the Breslow-Day x2 test of homogeneity.37 If an interaction
was observed, results were presented for each category of age at
last follow-up. In both analyses, if no information was available
for a patient’s given clinical feature, he or she was excluded from
the analysis of that speciﬁc lesion.
To study the effect of mutation types, we compared (1) patients
with a PTC with patients with an inframe mutation, (2) patients
with a particular subtype of mutation (nonsense, frameshift,
splicing, missense, or inframe deletions/insertions) 2 by 2, and
(3) patients with missense mutations eliminating or creating a
cysteine. There was no recurrent mutation frequent enough to
allow a correlation study regarding the other FBN1 mutations. To
study the consequences of mutations in different structural and
functional domains, we compared (1) patients with a mutation
located in an EGF domain (cb and non-cb) with those with a
mutation located in a TGFb-BP domain; (2) patients with a mu-
tation at the 5′ end of the FBN1 gene (exon 1–21, inclusive) with
those with a mutation at the 3′ end of the gene (exon 43–65,
inclusive), to take into account the regions involved in the pro-
cessing of the protein; (3) patients with amutation locatedwithin
the so-called neonatal region (exons 24–32) with those with a
mutation located in other exons; and (4) patients with amutation
located within the TGFb1 regulating sequence (exons 44–49)with
those with a mutation located in other exons. When locations
of mutations were compared, studies were performed with all
types ofmutations andwithmissensemutations alone, to exclude
a bias due to different types of mutations. Mutations located in
exons 24–32 were compared with mutations located elsewhere,
with and without the inclusion of neonatal MFS.
SAS software version 9.2 and Stata software version 8 were used
for all statistical analyses. Only P values !.001 were considered
signiﬁcant, since multiple tests were performed.
Results
Mutations
A total of 803 pathogenic mutations were found in 1,013
probands (including 114 recurrent mutations in 324
probands). The distribution of mutations is presented in
ﬁgure 1. Of the missense mutations, 61% (348 of 573)
involved a cysteine (284 replacing and 64 creating a cys-
teine). Sixty-eight percent (665 of 984) were inframe,
whereas 32% (319 of 984) generated a PTC (29 splicing
mutations were not classiﬁed, since the consequence at
themRNA level could not be determined unambiguously).
The majority of mutations were located in an EGF domain
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Figure 1. Types of FBN1 mutations included in the study. Of
1,013, 573 (56%) could be classiﬁed as missense mutations, 170
(17%) as frameshift mutations, 137 (14%) as nonsense mutations,
110 (11%) as splicing mutations, and 23 (2%) as inframe deletions
or insertions.
(74% [747 of 1,013])—701 of which were located in a cb-
EGF domain—and 15% (153 of 1,013) were located in a
TGFb-BP domain. Twenty-nine percent (293 of 1,013) of
mutations were found in the 5′ region of the gene, and
379 (37%) were found in the 3′ region of the gene. Twenty
percent (198 of 1,013) of mutations were located in exons
24–32. Ten percent (102 of 1,013) of mutations were lo-
cated in exons 44–49. No major differences in mutation-
type categories were detected between laboratories.
Phenotype in the Overall Patient Cohort
Fifty-four percent of patients were males and 46% were
females. A family history of MFS was found in 52% of
cases. The median age at last follow-up was 29 years (in-
terquartile range [IQR] 15–40 years), including 322 pa-
tients aged !18 years (32%). The median age at diagnosis
of type I ﬁbrillinopathy was 20 years (IQR 9–34 years).
Five percent of patients ( ) had a neonatal presen-np 48
tation. Overall, at the time of analysis, 61 (6%) had died,
31 (51%) in the context of neonatal MFS, 19 of aortic
dissection, 10 during or after aortic surgery, and 1 from a
cause unrelated to MFS.
The frequency of manifestations of each organ system
in the full cohort of patients is listed in table 2. In par-
ticular, of the 1,013 patients, 145 (14%) had dissection of
the ascending aorta, 43 (4%) had dissection of the de-
scending aorta, and 30 (3%) had dissection of the abdom-
inal aorta. Protrusio acetabulae and dural ectasia—al-
though they are included in the Ghent nosology—were
rarely looked for in our patients ( and ,np 298 np 292
respectively). The majority (89%) of patients could be clas-
siﬁed, according to Ghent nosology, as havingMFS at their
last follow-up, when the presence of an FBN1 mutation
was considered a major feature (72% when the presence
of an FBN1 mutation was not considered a major feature).
Phenotypic differences depending on the sex of the pro-
band were studied for all clinical parameters. Signiﬁcant
differences were found only for the cumulative probability
of aortic surgery for patients with aortic dilatation. Indeed,
46% of males had surgery for aortic dilatation before or
at age 40 years (99.9% CI 38%–55%) compared with 34%
of females (99.9% CI 26%–50%) ( ). A marginallyPp .0002
signiﬁcant result was found for the cumulative probability
of ascending aortic dilatation, with a probability of 80%
before or at age 40 years in males (99.9% CI 5%–84%)
compared with 70% in females (99.9% CI 64%–76%)
( ).Pp .0036
Types of Mutations
Missense mutations substituting or creating a cysteine versus
other missense mutations.—The probability of ectopia lentis
was signiﬁcantly higher with missense mutations involv-
ing a cysteine when compared with other missense mu-
tations (log-rank test ) (ﬁg. 2). The cumulativeP ! .0001
probability of ectopia lentis diagnosed before or at age 25
years was 59% (99.9% CI 50%–68%) for patients withmis-
sense mutations involving a cysteine compared with 32%
(99.9%CI 22%–44%) for patients with othermissensemu-
tations. Consequently, the percentage of patients with
positive Ghent criteria was higher in the group of patients
with missense mutations involving a cysteine when com-
pared with other missense mutations (76% vs. 63% when
the presence of an FBN1 mutation was not considered as
a major feature; MH test ).Pp .0003
PTC versus inframe mutations.—Patients with a PTC mu-
tation more frequently had major skeletal involvement
(40% vs. 28%; MH test ) with a higher propor-Pp .0008
tion of arachnodactyly, dolichostenomelia, joint hyper-
laxity, pectus deformity, high-arched palate, and pes
planus. Moreover, a higher frequency of striae distensae
(64% vs. 40%; MH test ) was observed in patientsP ! .0001
with a PTC mutation (ﬁg. 3). The cumulative probability
of a diagnosis of ascending aortic dilatation before or at
age 40 years was 77% (99.9% CI 8%–85%) for patients
with PTC mutations compared with 74% (99.9% CI 67%–
80%) for patients with an inframe mutation (log-rank test
). Conversely, the cumulative probability of aPp .7791
diagnosis of ectopia lentis and ophthalmologic surgery
was signiﬁcantly lower for patients with PTC mutations
compared with patients with an inframe mutation (log-
rank test and , respectively) (table 3P ! .0001 Pp .0001
and ﬁgure 2). These results became insigniﬁcant for the
age at diagnosis of ectopia lentis and ophthalmologic
surgery when patients with PTC mutations were com-
pared with patients with missense mutations not involv-
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Figure 2. Kaplan-Meier analyses for the probability of ectopia lentis diagnoses for patients with different types of mutations. A,
Probability of ectopia lentis in PTC versus inframe mutations. The cumulative probability of diagnosis of ectopia lentis before or at age
25 years was 23% (99.9% CI 15%–32%) for patients with PTC mutations (thin line) compared with 50% (99.9% CI 43%–57%) for
patients with inframe mutations (thick line) (log-rank test ). B, Probability of ectopia lentis for patients with missense mutationP ! .0001
involving a cysteine versus other missense mutations. The cumulative probability of diagnosis of ectopia lentis before or at age 25
years was 59% (99.9% CI 50%–68%) for patients with missense mutations involving a cysteine (thin line) compared with 32% (99.9%
CI 22%–44%) for patients with other missense mutations (thick line) (log-rank test ).P ! .0001
ing a cysteine (log-rank test and ,Pp .0424 Pp .1020
respectively).
Other mutation subtypes.—As expected for the results of
PTC mutations versus inframe mutations, a lower prob-
ability of ectopia lentis was found when nonsense or
frameshift mutations were compared with missense mu-
tations (log-rank test ). No signiﬁcant differenceP ! .0001
was found for any manifestation when patients with non-
sense mutations were compared with those with frame-
shift mutations or when patients withmissensemutations
were compared with those with splicing mutations. A
higher probability of ascending aortic dilatation (log-rank
test ) and mitral valve prolapse (log-rank testP ! .0001
) and a higher frequency of arachnodactyly andPp .0007
joint laxity (MH test and , respec-Pp .0002 Pp .0006
tively) were found in patients with amutation eliminating
a cysteine than in patients with a mutation creating a
cysteine.
Location of Mutations
Exons 24–32 versus other exons.—A neonatal onset of the
disease was found in 22% ( ) of patients with a mu-np 42
tation in exons 24–32, compared with 0.6% ( ) ofnp 4
patients with a mutation in other exons (x2 test P !
). When patients with mutations within exons 24–.0001
32 were compared with patients with mutations in the
other exons, signiﬁcant differences were found for joint
limitations (34% vs. 11%; MH test ), scoliosis,P ! .0001
ectopia lentis, ascending aortic dilatation, aortic surgery,
mitral valve abnormalities (mitral valve prolapse, mitral
regurgitation, and/or mitral surgery), younger age at di-
agnosis of type I ﬁbrillinopathy, and a shorter overall sur-
vival (log-rank test ) (table 3 and ﬁg. 4). Indeed,P ! .001
76% of patients with mutations in exons 24–32 were alive
at age 40 years (99.9% CI 61%–87%) compared with 98%
(99.9% CI 93%–99%) of patients with mutations located
in other exons (log-rank test ). Moreover, the cu-P ! .0001
mulative probability of ascending aortic dilatation diag-
nosed before or at age 40 years was 87% (99.9% CI 77%–
95%) for patients with a mutation in exons 24–32 com-
pared with 72% (99.9% CI 67%–78%) for patients with a
mutation in other exons (log-rank test ), and theP ! .0001
cumulative probability of aortic surgery before or at age
40 years was 55% (99.9% CI 35%–77%) for patients with
a mutation in exons 24–32 compared with 38% (99.9%
CI 30%–48%) for patients with a mutation in other exons
(log-rank test ). Apart from ectopia lentis, the re-P ! .0001
sults were similar when patients with a neonatal onset
were excluded. Results were also similar when all types of
mutations were included in the analysis and when only
missense mutations (except for ectopia lentis) or onlymis-
sense mutations involving a cysteine were included.
The distribution of types of mutations was signiﬁcantly
different in exons 24–32 from the distribution in the other
exons, with an overrepresentation of missense mutations
and an underrepresentation of nonsense mutations (table
4) (Fischer test ). PTC mutations within exonsPp .0002
24–32 were rarely associated with a neonatal MFS presen-
tation (2 [5%] of 43) compared with inframe mutations
within this region (41 [95%] of 43). A higher frequency
of neonatal presentations was found for mutations in
exon 25 when compared with mutations distributed in
exons 24–32 (x2 test ).P ! .0001
Exons 44–49 versus other exons.—No signiﬁcantdifference
was found for any clinical parameter for patients with a
mutation located in the speciﬁc sequence that regulates
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Figure 3. Frequency of skeletal, skin, pulmonary, and dural phenotypes in study participants with PTC mutations (gray bars), compared
with those with inframe mutations (black bars). An asterisk (*) indicates that differences between groups were statistically signiﬁcant
(MH test ).P ! .001
the bioavailability of endogenous TGFb1, compared with
those with a mutation located elsewhere.
EGF/TGF b-BP domains.—No signiﬁcant difference was
found for any clinical parameter for patients with a mu-
tation located in an EGF domain compared with those
with a mutation in a TGFb-BP domain, nor between pa-
tients with a mutation in a cb-EGF domain and those with
a mutation in a non–cb-EGF domain. Similar results were
found when all types of mutations or only missense mu-
tations were included in the analysis.
5′ versus 3′ mutations.—Patients with a mutation located
in the 5′ region of the gene had a higher probability of
ectopia lentis (log-rank test ). This result wasPp .001
highly signiﬁcant when only missense mutations were in-
cluded in the analysis (log-rank test ), whereasP ! .0001
all the other results remained nonsigniﬁcant.
Discussion
FBN1 mutations have been associated with a broad spec-
trum of phenotypes now often called “type I ﬁbrillino-
pathies,” ranging from single connective-tissue manifes-
tations, such as isolated ectopia lentis, to MFS and lethal
neonatal MFS. Every patient with an FBN1 mutation is at
risk for developing severe cardiovascular, skeletal, and
ophthalmologic complications (L. Faivre, G. Collod-Be-
roud, B. Loeys, A. Child, C. Binquet, E. Gautier, B. Cal-
lewaert, E. Arbustini, K. Mayer, M. Arslan-Kirchner, A.
Kiotsekoglou, P. Comeglio, N. Marziliano, D. Halliday, C.
Beroud, C. Bonithon-Kopp, M. Claustres, H. Plauchu, P.
N. Robinson, L. Ade`s, J. De Backer, P. Coucke, U. Francke,
A. De Paepe, C. Boileau, G. Jondeau, unpublished data).
Here, we aimed at identifying the type or location of a
given FBN1 mutation that could be associated with the
presence of a clinical feature, severity, and/or age at onset.
Although no speciﬁc manifestation or set of features is
pathognomonic for a particular subtype of FBN1 muta-
tion, the occurrence of speciﬁc organ involvementdiffered
signiﬁcantly in some instances.
The mechanism by which mutations in FBN1 result in
disease is unclear, since the biochemical pathway of ﬁ-
brillin-1 assembly into microﬁbrils is still poorly under-
stood and since the role of ﬁbrillin-1 in TGFb signaling
has only recently emerged. A dominant negative model
was ﬁrst proposed,38–39 in which the mutant monomer dis-
rupts assembly of normal ﬁbrillin-1 into microﬁbrils or is
itself misincorporated into the microﬁbril. Recent studies
have given evidence of a critical contribution of haploin-
sufﬁciency in the pathogenesis of MFS.40 Different effects
on trafﬁcking have also been demonstrated, with some
mutations acting as dominant negative and others as hap-
loinsufﬁcient.41 Here, our data suggest that both genetic
mechanisms are involved and that their tissue distribution
may differ.
The ﬁrst striking result of this study is the strong cor-
relation found between ectopia lentis and the presence of
a mutation affecting a cysteine residue, conﬁrming earlier
conclusions on a smaller sample.24–27,42 It is noteworthy
that phenotypes strongly overlapping with type I ﬁbril-
linopathies are associated with mutations in TGFBR1/2
and thus altered TGFb signaling. However, the main fea-
ture of these phenotypes, as compared with type I ﬁbril-
linopathies, is the almost consistent absence of ocular
involvement.43 Thus, it could be speculated that the func-
tional aspect of ﬁbrillin-1 that is altered in patients with
ectopia lentis is not involved in TGFb signaling but is a
structural function in the extracellular matrix. Our data
suggest that correct cysteine localization and disulﬁde
bonding play an important role in the structural integrity
of the suspensory ligaments of the lens, itself relying on
the structural function of ﬁbrillin-1 in this organ.44 Also,
in the subgroup of patients with a mutation affecting a
cysteine residue, we found a signiﬁcantly higher proba-
bility of ascending aortic dilatation and mitral valve pro-
Table 3. Comparison of Probabilities of Clinical-Feature Diagnosis at a Speciﬁc Age for Patients with MFS and Other Type I Fibrillinopathies, According to the
Type or Location of FBN1 Mutations
Frequency
Probabilities of
Clinical Features
Diagnosis (%) at Age
Frequency
Probabilities of
Clinical Features
Diagnosis (%) at Age
n (%) 10 25 40 n (%) 10 25 40
Clinical Feature PTC Mutations Inframe Mutations Pa
Age at diagnosis of type I ﬁbrillinopathy 319 100.0 20.4 51.7 85.2 665 100.0 32.3 61.2 86.9 .0103
Ascending aortic dilatation 259 81.2 10.6 38.7 76.9 491 73.8 20.2 43.5 73.8 .7791
Aortic dissection in the population presenting with ascending aortic dilatation 65 25.1 .0 3.6 31.1 78 15.9 .2 5.1 22.9 .2014
Aortic surgery in the population presenting with ascending aortic dilatation 102 39.4 .0 9.4 42.0 147 29.9 1.8 12.2 40.4 .5301
Survival 303 95.0 99.7 98.8 95.1 43 6.5 95.5 94.4 93.2 .2311
Missense Mutations Involving a Cysteine Other Missense Mutations
Age at diagnosis of type I ﬁbrillinopathy 348 100.0 32.8 62.6 89.1 225 100.0 28.9 57.8 82.2 .0983
Ascending aortic dilatation 262 75.3 21.3 46.3 75.6 158 70.2 17.6 37.4 69.4 .0797
Aortic dissection in the population presenting with ascending aortic dilatation 41 15.6 .0 4.6 29.9 25 15.8 .7 5.2 10.8 .4249
Aortic surgery in the population presenting with ascending aortic dilatation 80 30.5 1.3 14.0 47.4 49 31.0 2.7 10.4 29.0 .2712
Survival 330 94.8 96.5 96.1 94.5 14 6.2 96.0 93.5 93.5 .6785
Exons 24–32 Other Exons
Age at diagnosis of type I ﬁbrillinopathy 198 100.0 51.0 75.8 91.9 815 100.0 23.1 53.7 85.2 !.0001
Ascending aortic dilatation 164 82.8 42.5 65.7 87.3 609 74.7 11.3 36.4 72.4 !.0001
Aortic dissection in the population presenting with ascending aortic dilatation 21 12.8 .7 5.8 28.5 124 20.4 .2 4.3 25.7 .3064
Aortic surgery in the population presenting with ascending aortic dilatation 52 31.7 4.7 17.5 55.2 201 33.0 .5 9.9 38.4 !.0001
Survival 159 80.3 84.5 81.1 76.1 22 2.7 99.6 99.1 97.5 !.0001
NOTE.—All ages are in years. Results are Kaplan-Meier estimates.
a Log-rank test P values were for PTC mutations versus inframe mutations, for missense mutations involving a cysteine versus other missense mutations, or for mutations within exons 24–
32 versus mutations in other exons.
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Table 4. Types of Mutations Found in Exons
24–32, Compared with Mutations in the Other Exons
Mutation
No. (%) of Mutations in
Exons 24–32
( )np 198
Other Exons
( )np 815
Nonsense 13 (6.6) 124 (15.2)
Frameshift 27 (13.6) 143 (17.5)
Splicing 15 (7.6) 95 (11.7)
Missense 139 (70.2a) 434 (53.3b)
Inframe deletion/insertion 4 (2.0) 19 (2.3)
NOTE.—Global Fischer exact test for differences was used,
according to the location of mutations. .Pp .0002
a 54% involving a cysteine.
b 63% involving a cysteine.
Figure 4. Kaplan-Meier analyses for the probability of MFS clinical-features diagnosis for patients with different locations of mutations.
A, Age at diagnosis of type I ﬁbrillinopathy with a mutation in exons 24–32 versus in other exons. Fifty percent of patients with a
mutation in exons 24–32 (thin line) received a diagnosis at age 9 years (IQR 1–24 years) versus age 24 years (IQR 12–35 years) of
patients with a mutation in other exons (thick line) (log-rank test ). B, Survival of patients with mutations in exons 24–32P ! .0001
versus in other exons. Seventy-six percent of patients with mutations within exons 24–32 (thin line) were alive at age 40 years (99.9%CI
61%–87% years) compared with 98% (99.9% CI 93%–99%) of patients with mutations located in other exons (thick line) (log-rank
test ). C, Probability of diagnosing a dilatation of the ascending aorta for patients with mutations in exons 24–32 versus inP ! .0001
other exons. The cumulative probability of diagnosis of ascending aortic dilatation before or at age 40 years was 87% (99.9% CI 77%–
95%) for patients with mutations in exons 24–32 (thin line) compared with 72% (99.9% CI 67%–78%) for patients with mutations in
other exons (thick line) (log-rank test ). D, Probability of aortic surgery for patients with mutations in exons 24–32 versus inP ! .0001
other exons. The cumulative probability of aortic surgery before or at age 40 years was 55% (99.9% CI 35%–77%) for patients with
mutations in exons 24–32 (thin line) compared with 38% (99.9% CI 30%–48%) for patients with mutations in other exons (thick line)
(log-rank test ). E, Probability of ectopia lentis for patients with mutations in exons 24–32 versus in other exons. TheP ! .0001
cumulative probability of ectopia lentis diagnosis before or at age 25 years was 53% (99.9% CI 39%–67%) for patients with mutations
in exons 24–32 (thin line) compared with 38% (99.9% CI 33%–44%) for patients with mutations in other exons (thick line) (log-rank
test ). F, Probability of scoliosis for patients with mutations in exons 24–32 versus in other exons. The cumulative probabilityPp .0003
of scoliosis diagnosis before or at age 25 years was 61% (99.9% CI 47%–75%) for patients with mutations in exons 24–32 (thin line)
compared with 44% (99.9% CI 38%–51%) for patients with mutations in other exons (thick line) (log-rank test ).P ! .0001
lapse and a higher frequency of arachnodactyly and joint
laxity, when comparing patients with a mutation elimi-
nating a cysteine with those with a mutation creating a
cysteine. Therefore, it seems that the disappearance of a
conserved cysteine residue implicated in a disulﬁde bond
leads to a more severe disorganization of a given module
than does the introduction of a new and supernumerary
cysteine residue.
The second striking result of our study is the strong
correlation between FBN1 PTC mutation and severe skel-
etal and skin phenotypes. Contrary to what is described
in the preceding paragraph, mutations in TGFBR1/2 are
associated with skeletal and sometimes skin alterations
highly comparable to those found in patients with FBN1.
Thus, it is expected that a function or pathway common
to ﬁbrillin-1 and the TGFb type 1/2 receptors is altered in
these patients. It could be speculated that haploinsufﬁ-
ciency for ﬁbrillin-1 in bone and skin has a stronger effect
on the TGFb signaling function of the protein than on its
structural function—and thus that, in bone growth, ﬁ-
brillin-1 acts as amediator of TGFb signaling. The different
correlations found for skeletal and skin manifestations on
the one hand versus the ocular system on the other hand
might then be explained by differences in the composition
and function of ﬁbrillin-rich microﬁbrils in different or-
gans and further underscore the complexity of the com-
position of microﬁbrils and their interactions within tis-
sues. Patients with a mutation in exons 24–32 had a more
severe and complete phenotype, including younger age at
diagnosis and higher probability of scoliosis, ectopia len-
tis, ascending aortic dilatation, aortic surgery, mitral valve
abnormalities, and shorter survival. However, patients
with aortic dilatation and a mutation in exons 24–32 did
not present a higher probability of aortic dissection than
did patients with aortic dilatation and a mutation located
elsewhere. These data can be explained in part by a higher
probability of aortic surgery in such patients. It can also
be postulated that, because of the general severity of the
phenotype, type I ﬁbrillinopathywas diagnosed before the
occurrence of aortic dissection in patients with amutation
in exons 24–32. Since the majority of these results were
replicated even when neonatal MFS cases were excluded,
we conclude that patients with a mutation in exons 24–
32 have a poorer prognosis, with earlier onset ofmorbidity
than in patients with a mutation located elsewhere. The
presence of a mutation in this region appears to be the
best indicator of early-onset aortic risk. More than a “neo-
natal region,” it should be considered a “severe region.”
This result can be explained by the role of these exons in
the central stretch of contiguous EGF-like domains and
their importance for alignment and stability of the 10-nm
microﬁbrils in the extracellular matrix.45 The distribution
of the mutation types in exons 24–32 is different from
the distribution found in other exons of the gene. Mu-
tations leading to PTC are signiﬁcantly underrepresented,
contrasting with an overrepresentation of inframe mu-
tations. In particular, nonsense mutations have never to
our knowledge been described in association with neo-
natal MFS, and this observation may be of importance
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in elucidating the pathogenetic role of the exon 24–32
region.
In this study, we sought to avoid the main bias inherent
in our study design. Clinical/molecular correlations are
complicated by a wide age range in individuals. In younger
patients, the clinical phenotype and symptoms may not
be fully developed. Indeed, incorrect signiﬁcant results
can be obtained when x2 tests are used, and the use of the
Kaplan-Meier approach allowed us to take into account
the heterogeneity of the length of follow-up among
groups, as well as the young median age of the patients
in the cohort. Since age at lesion onset cannot be assessed
for MFS, notably for aortic dilatation, we used the ages at
which each main clinical manifestation was discovered.
We considered only probands, to minimize the possible
inﬂuence of early medical interventions in relatives (ear-
lier monitoring and earlier preventive therapy with b-
blockers) and to avoid overrepresentation of a mutation.
Finally, we also excluded patients (4%) for whom no in-
formation about one of themajor systems ofMFS (cardiac,
ocular, and skeletal system) was available. The lownumber
of excluded patients had no signiﬁcant impact on our
results but provided a homogeneous study population,
whatever the clinical feature investigated. However, it
should be noted that the majority of patients were of Eu-
ropean origin, thus the conclusions may not be totally
applicable to all ethnic groups. Another aspect of the pro-
band collection is the high frequency of de novo muta-
tions. It is now well documented that the yield in mu-
tation screening is highest in probands displaying an MFS
phenotype diagnosed using the Ghent nosology.24 Fur-
thermore, molecular conﬁrmation of an apparent de novo
event is important for genetic counseling in at-risk rela-
tives. Therefore, the important number of de novo mu-
tations found in the probands does not reveal a higher-
than-reported mutation rate but reﬂects practices and
screening results from the contributing centersworldwide.
A few studies have addressed the question of a genotype-
phenotype correlation in FBN1 carriers. Only ﬁve included
a sufﬁcient number of patients (101, 93, 57, 81 and 76
patients)23–27 to draw conclusions. A simple x2 approach
was used, and probands as well as their affected family
members were considered in two of the ﬁve series. Authors
mainly compared the different phenotypes related to PTC
mutations with those of cysteine substitutions. A signiﬁ-
cantly higher frequency of ectopia lentis associated with
cysteine substitutions when compared with PTC muta-
tions was a consistent ﬁnding. A tendency toward a more
severe skeletal phenotype23–24 and a more severe cardiac
phenotype23,27 in the PTC group was discussed, but with
inconsistency in signiﬁcant results. This could be ex-
plained partly by the small sample sizes of the populations
studied. The protein phenotypes were studied only by
Schrijver et al.23 A preponderance of probands with PTC
mutations had markedly reduced extracellular ﬁbrillin de-
position with reduced synthesis, whereas individuals with
cysteine substitutions had normal levels of ﬁbrillin syn-
thesis and markedly reduced matrix deposition. Geno-
type-phenotype correlations in type I ﬁbrillinopathies
have also been complicated by clinical heterogeneity
among individuals with the same mutation, within and
among families.46–48 The type or location of a mutation
alone cannot explain these variations. The existence of
genetic or environmental modiﬁers, as well as the suscep-
tibility of microﬁbrillar matrices to proteolytic degrada-
tion, or intrafamilial variation in FBN1 expression have
been postulated.40,49
In conclusion, our results show a strong correlation be-
tween ectopia lentis and the presence of a mutation af-
fecting a cysteine residue, whatever its location within the
protein. Conversely, PTC mutations are associated with
severe skeletal and skin phenotypes. These correlations
found between different mutation types and clinicalman-
ifestations may indicate different underlying pathophys-
iologic mechanisms, both genetic (dominant negative vs.
haploinsufﬁciency) and functional (structural function of
ﬁbrillin-1 vs. mediator of TGFb signaling). Finally, we
show that the location of a mutation within the exon 24–
32 region is associated with a severe prognosis, not only
in newborns but at all ages. However, we believe that these
results cannot be used for individual prognosis but show
that aortic monitoring is warranted in every patient with
an FBN1 mutation.
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